Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.35), $0.06 worse than the analyst estimate of ($0.29).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.